Experience

Selux Diagnostics, Inc

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Director of Research and Development

  • Jan 2023 - Present

• Director of Microbiology

  • Jan 2021 - Present

• Lead Microbiologist

  • Jan 2018 - Jan 2021

  Selux Diagnostics, Inc is pioneering a new era in personalized medicine with the development of a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease treatment by dramatically increasing the speed and accuracy with which targeted antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global… Show more Selux Diagnostics, Inc is pioneering a new era in personalized medicine with the development of a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease treatment by dramatically increasing the speed and accuracy with which targeted antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. The CDC has cited bacterial resistance to antibiotics among the world’s deadliest and costliest health threats. Using current technologies, doctors must overprescribe powerful, broad-spectrum antibiotics for days while waiting for key diagnostic results to direct personalized therapy. Selux’s Next Generation Phenotyping (NGP) system provides virtually instantaneous AST results, fast-tracking targeted patient therapies so patients can receive the treatments they need on day one.

• Senior Scientist

  • Oct 2016 - Jan 2018



Washington University in St. Louis

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Associate

  • Oct 2011 - Aug 2016

  • Developed a novel assay to screen for chemical inhibition of stress responses in Mycobacterium tuberculosis (Mtb), M. abscessus, M. marinum, and M. smegmatis, which led to the identification of novel antimycobacterial compounds. • Characterized the biochemical mechanism of inhibitors of bacterial antibiotic tolerance, antibiotic resistance, and biofilm formation in an effort to develop new drugs to treat tuberculosis. • Utilized large-scale lipidomic and transcriptional approaches to… Show more • Developed a novel assay to screen for chemical inhibition of stress responses in Mycobacterium tuberculosis (Mtb), M. abscessus, M. marinum, and M. smegmatis, which led to the identification of novel antimycobacterial compounds. • Characterized the biochemical mechanism of inhibitors of bacterial antibiotic tolerance, antibiotic resistance, and biofilm formation in an effort to develop new drugs to treat tuberculosis. • Utilized large-scale lipidomic and transcriptional approaches to define new aspects of Mtb stress responses. • Initiated and guided collaboration efforts with a chemistry group at Washington University to characterize inhibitors of glutamine synthetase in Mtb. • Led hit verification and analysis in a dual-university, multi-lab high-throughput screening collaboration aiming to identify and develop drugs targeting the stress-responsive Mtb Rel enzyme. Show less • Developed a novel assay to screen for chemical inhibition of stress responses in Mycobacterium tuberculosis (Mtb), M. abscessus, M. marinum, and M. smegmatis, which led to the identification of novel antimycobacterial compounds. • Characterized the biochemical mechanism of inhibitors of bacterial antibiotic tolerance, antibiotic resistance, and biofilm formation in an effort to develop new drugs to treat tuberculosis. • Utilized large-scale lipidomic and transcriptional approaches to… Show more • Developed a novel assay to screen for chemical inhibition of stress responses in Mycobacterium tuberculosis (Mtb), M. abscessus, M. marinum, and M. smegmatis, which led to the identification of novel antimycobacterial compounds. • Characterized the biochemical mechanism of inhibitors of bacterial antibiotic tolerance, antibiotic resistance, and biofilm formation in an effort to develop new drugs to treat tuberculosis. • Utilized large-scale lipidomic and transcriptional approaches to define new aspects of Mtb stress responses. • Initiated and guided collaboration efforts with a chemistry group at Washington University to characterize inhibitors of glutamine synthetase in Mtb. • Led hit verification and analysis in a dual-university, multi-lab high-throughput screening collaboration aiming to identify and develop drugs targeting the stress-responsive Mtb Rel enzyme. Show less



The BALSA Group

• United States
• Business Consulting and Services
• 1 - 100 Employee

• Project Manager and Consultant

  • Oct 2015 - Jul 2016

  • Led and managed a team of consultants conducting market research for a biotechnology startup company. • Performed primary and secondary research to advise multiple clients on market entry and expansion opportunities. • Led and managed a team of consultants conducting market research for a biotechnology startup company. • Performed primary and secondary research to advise multiple clients on market entry and expansion opportunities.



Washington University in St. Louis

• United States
• Higher Education
• 700 & Above Employee

• Graduate Student

  • 2004 - 2011

  • Designed the first promoter trap assay to detect Salmonella gene activation events in response to cancer cells, which identified five bacterial genes involved in interactions with cancer cells. • Constructed a Salmonella reporter strain with real-time, tumor-specific gene activation in vivo. • Created a conditionally toxic Salmonella strain activated by the tumor microenvironment for bacteria-based cancer therapy proof-of-concept in a mouse model. • Developed and executed an siRNA… Show more • Designed the first promoter trap assay to detect Salmonella gene activation events in response to cancer cells, which identified five bacterial genes involved in interactions with cancer cells. • Constructed a Salmonella reporter strain with real-time, tumor-specific gene activation in vivo. • Created a conditionally toxic Salmonella strain activated by the tumor microenvironment for bacteria-based cancer therapy proof-of-concept in a mouse model. • Developed and executed an siRNA assay that targeted >900 host kinases and phosphatases and identified novel host factors involved in the inflammatory response to Salmonella. • Authored a series of high impact, peer-reviewed publications on Salmonella and bacteria-host interactions. Show less • Designed the first promoter trap assay to detect Salmonella gene activation events in response to cancer cells, which identified five bacterial genes involved in interactions with cancer cells. • Constructed a Salmonella reporter strain with real-time, tumor-specific gene activation in vivo. • Created a conditionally toxic Salmonella strain activated by the tumor microenvironment for bacteria-based cancer therapy proof-of-concept in a mouse model. • Developed and executed an siRNA… Show more • Designed the first promoter trap assay to detect Salmonella gene activation events in response to cancer cells, which identified five bacterial genes involved in interactions with cancer cells. • Constructed a Salmonella reporter strain with real-time, tumor-specific gene activation in vivo. • Created a conditionally toxic Salmonella strain activated by the tumor microenvironment for bacteria-based cancer therapy proof-of-concept in a mouse model. • Developed and executed an siRNA assay that targeted >900 host kinases and phosphatases and identified novel host factors involved in the inflammatory response to Salmonella. • Authored a series of high impact, peer-reviewed publications on Salmonella and bacteria-host interactions. Show less



The University of Kansas

• United States
• Higher Education
• 700 & Above Employee

• Undergraduate Research Assistant

  • Aug 2001 - May 2004

  • Utilized biochemical, microbiological and molecular biological approaches to define features of secreted virulence factors in the pathogen Shigella flexneri. • Utilized biochemical, microbiological and molecular biological approaches to define features of secreted virulence factors in the pathogen Shigella flexneri.